The effect of virechan and rasnasaptak kwath in the management of Amavata.

A clinical study on the effect of Virechan and Rasnasaptak Kwath in the management of Amavata w.s.r to Rheumatoid Arthritis. - RSK

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036858

Enrollment

Registered

2021-09-27

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient having sign & symptoms of Amavata as mentioned in Madav Nidan. The patient of R.A. fulfilling the assessment criteria ACR/EULAR 2010. Both seropositive & seronegative cases of R.A Patients of both gender & middle age group.

Exclusion criteria

Exclusion criteria: Patiens in gouty arthritis, septic arthritis, osteoarthritis & ankylosis spondylitis. Patients having severe degree of deformity & complications, as per upadravas describe in ayurvedic texts like Madav Nidan Pregnancy & lactation

Design outcomes

Primary

Measure	Time frame
Improvement in AmavataTimepoint: 45 days	—

Secondary

Measure	Time frame
Improvement symptoms of AmavataTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Arunima kumari

ARYABHATT KNOWLEDGE UNIVERSITY

drdineshwarprasad@gmail.com9470019814

Outcome results